{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:31:44Z","timestamp":1791491504515,"version":"4.3.4"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Food\u2013drug interactions are common in orally administered therapies. In order to achieve optimal therapeutic efficacy and safety, it is important for patients to understand the most appropriate way to take their medications in accordance with their diet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the impact of food on the oral bioavailability of novel cardiovascular and antidiabetic drugs, including sacubitril\/valsartan, direct oral anticoagulants, sodium-glucose cotransporter-2 inhibitors, semaglutide, vericiguat, pitavastatin, and bempedoic acid.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Scopus, and Cochrane Library databases were searched from inception to May 2024, following the guidelines of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) statement. The search strategy employed keywords including \u2018food drug interactions\u2019, \u2018food effect\u2019, \u2018bioavailability\u2019, and \u2018bioequivalence\u2019, combined with the names of the investigated drugs. Eligible publications comprised clinical pharmacokinetic studies and randomized clinical trials evaluating the effect of food on drug bioavailability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 36 publications met the inclusion criteria. For most drugs, food was found to reduce the maximum concentration and delay the rate of absorption of the active substance without significantly affecting overall drug exposure. Therefore, these drugs can generally be administered regardless of meals. Semaglutide is recommended to be administered on an empty stomach, and pitavastatin demonstrated higher bioavailability in the fasted state. In contrast, vericiguat and higher doses of rivaroxaban are better absorbed when taken with food. For patients with swallowing difficulties, rivaroxaban, apixaban, and edoxaban may be crushed and administered either via a nasogastric tube or orally mixed with applesauce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For a substantial proportion of novel cardiovascular and antidiabetic therapies, dosing without strict regard to meals is supported by available evidence. This level of flexibility may facilitate patient adherence and contribute to improved therapeutic outcomes in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1786007","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:10:41Z","timestamp":1777277441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Food-drug interactions of novel drugs used in cardiologic and diabetic patients \u2013 a PRISMA scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Iga","family":"Paw\u0142owska","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Ku\u017abicka","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kowalczys","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Paw\u0142owski","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Koci\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107627","DOI":"10.1124\/dmd.107.015511","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: consequences for the personalization of drug treatment","volume":"215","author":"Aitken","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/S13318-016-0354-1","article-title":"Pharmacokinetics after single ascending dose, food effect, and safety of sacubitril\/valsartan (LCZ696), an angiotensin receptor and neprilysin inhibitor, in healthy Japanese subjects","volume":"42","author":"Akahori","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res. Official J. Am. Assoc. Pharm. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/CPDD.1297","article-title":"Phase 1, Single- and multiple-ascending-dose, food-effect, and East Asian subject studies to assess the pharmacokinetics, safety, and tolerability of bempedoic acid, a selective inhibitor of adenosine triphosphate citrate lyase","volume":"12","author":"Amore","year":"2023","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/J.1365-2125.2005.02462.X","article-title":"Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin","volume":"60","author":"Ando","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol. Theory Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMOA1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/S12020-013-0065-1\/TABLES\/2","article-title":"Decrease in TSH levels after lactose restriction in Hashimoto\u2019s thyroiditis patients with lactose intolerance","volume":"46","author":"Asik","year":"2014","journal-title":"Endocrine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.5414\/CP202604","article-title":"Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril\/valsartan (LCZ696) in healthy subjects","volume":"54","author":"Ayalasomayajula","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","article-title":"Clinical pharmacokinetics of sacubitril\/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor","volume":"56","author":"Ayalasomayajula","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/JPS.24696","article-title":"Literature review of gastrointestinal physiology in the elderly, in pediatric patients, and in patients with gastrointestinal diseases","volume":"105","author":"Bai","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/S13300-021-01078-Y","article-title":"Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like Peptide-1 analogue in a tablet formulation","volume":"12","author":"B\u00e6kdal","year":"2021","journal-title":"Diabetes Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated Statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/CHILDREN2020244","article-title":"Influence of food on paediatric gastrointestinal drug absorption following oral administration: a review","volume":"2","author":"Batchelor","year":"2015","journal-title":"Children"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S41120-022-00063-4","article-title":"Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics","volume":"8","author":"Becker","year":"2022","journal-title":"AAPS Open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/S002590050298","article-title":"Comparison of total and compartmental gastric emptying and antral motility between healthy men and women","volume":"25","author":"Bennink","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ihj.2022.04.003","article-title":"Safety and efficacy of ARNI (Valsartan\/Sacubitril) vs ACEI (Enalapril) in acute heart failure \u2013 a prospective observational study","volume":"74","author":"Bhat","year":"2022","journal-title":"Indian Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1208\/S12248-022-00687-0","article-title":"State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40262-020-00935-6","article-title":"Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase I studies in healthy volunteers","volume":"60","author":"Boettcher","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/S00228-020-03023-7","article-title":"Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects","volume":"77","author":"Boettcher","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.CLINTHERA.2015.11.010","article-title":"Fed and fasted single-dose assessment of bioequivalence of dapagliflozin and metformin extended-release fixed-dose combination tablets relative to single-component dapagliflozin and metformin extended-release tablets in healthy subjects","volume":"38","author":"Boulton","year":"2016","journal-title":"Clin. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/SCITRANSLMED.AAR7047\/SUPPL_FILE\/AAR7047_SM","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/S40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2217\/nnm-2016-0138","article-title":"A solid self-nanoemulsifying system of the BCS class IIb drug dabigatran etexilate to improve oral bioavailability","volume":"11","author":"Chai","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/J.CLINTHERA.2015.05.004","article-title":"Bioequivalence, food effect, and steady-state assessment of dapagliflozin\/metformin extended-release fixed-dose combination tablets relative to single-component dapagliflozin and metformin extended-release tablets in healthy subjects","volume":"37","author":"Chang","year":"2015","journal-title":"Clin. Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1021\/JS960085V","article-title":"Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH","volume":"86","author":"Charman","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5414\/CP202737","article-title":"A single and multiple postprandial dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban in healthy Chinese volunteers","volume":"55","author":"Chen","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/PHAR.2432","article-title":"Pharmacokinetics, safety, and bioequivalence of two empagliflozin formulations after single oral administration under fasting and fed conditions in healthy Chinese subjects: an open-label randomized single-dose two-sequence, two-treatment, two-period crossover study","volume":"40","author":"Chen","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12070672","article-title":"Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool","volume":"12","author":"Cheng","year":"2020","journal-title":"Pharmaceutics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.2174\/138920012800840464","article-title":"Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus","volume":"13","author":"Chetty","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/PHARMACEUTICS13010070","article-title":"Improved manufacturability and in vivo comparative pharmacokinetics of dapagliflozin cocrystals in beagle dogs and human volunteers","volume":"13","author":"Cho","year":"2021","journal-title":"Pharmaceutics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2018.1.348","article-title":"Role of the anticoagulant monitoring service in 2018: beyond warfarin","volume":"2018","author":"Clark","year":"2018","journal-title":"Hematology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1345\/APH.1E650","article-title":"Evaluation of presence of aspirin-related warnings with willow bark","volume":"39","author":"Clauson","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/J.ADDR.2007.08.043","article-title":"Predicting drug disposition, absorption\/elimination\/transporter interplay and the role of food on drug absorption","volume":"60","author":"Custodio","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/NATURE12820","article-title":"Diet rapidly and reproducibly alters the human gut microbiome","volume":"505","author":"David","year":"2014","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/CPDD.220","article-title":"Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability","volume":"5","author":"de Bruin","year":"2016","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/2589977511666191210151120","article-title":"The evaluation of valsartan biopharmaceutics properties","volume":"12","author":"de Castro","year":"2020","journal-title":"Curr. Drug Res. Rev."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes11121509","article-title":"Distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics","volume":"11","author":"de Jong","year":"2020","journal-title":"Genes (Basel)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/S40265-017-0832-Z","article-title":"A review of food-drug interactions on oral drug absorption","volume":"77","author":"Deng","year":"2017","journal-title":"Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/CPDD.151","article-title":"Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants","volume":"4","author":"Devineni","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/J.BLRE.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S40262-017-0554-0","article-title":"An open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults","volume":"57","author":"Duchin","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/nu14010212","article-title":"Interactions between food and drugs, and nutritional status in renal patients: a narrative review","volume":"14","author":"D\u2019Alessandro","year":"2022","journal-title":"Nutrients"},{"key":"B45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0009-9236(99)70102-5","article-title":"6\u2019,7\u2019-Dihydroxybergamottin in grapefruit juice and Seville Orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein","volume":"65","author":"Edwards","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/JPHP.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption \u2013 implications for formulation design \u2013 a PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/S11095-008-9749-2","article-title":"Meal-induced acceleration of tablet transit through the human small intestine","volume":"26","author":"Fadda","year":"2009","journal-title":"Pharm. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/S40262-020-00875-1","article-title":"Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor","volume":"59","author":"Fediuk","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3390\/PHARMACEUTICS16111371","article-title":"Bempedoic acid, the first-in-class oral ATP citrate lyase inhibitor with hypocholesterolemic activity: clinical pharmacology and drug\u2013drug interactions","volume":"16","author":"Ferri","year":"2024","journal-title":"Pharmaceutics"},{"key":"B50","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/J.1365-2125.2012.04369.X","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5414\/CP202929","article-title":"Relative bioavailability of an empagliflozin 25-mg\/linagliptin 5-mg fixed-dose combination tablet","volume":"55","author":"Glund","year":"2017","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/J.DRUDIS.2018.11.009","article-title":"Gut reaction: impact of systemic diseases on gastrointestinal physiology and drug absorption","volume":"24","author":"Hatton","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B53","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1208\/S12248-015-9845-2","article-title":"BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs","volume":"18","author":"Hosey","year":"2015","journal-title":"AAPS J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"B56","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/J.1463-1326.2011.01397.X","article-title":"Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"B57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/S40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose Co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"B58","article-title":"\u201cMedication Routes of Administration.\u201d In StatPearls [Internet]","author":"Kim","year":"2026"},{"key":"B59","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/S11095-021-03039-3","article-title":"Investigating intestinal transporter involvement in rivaroxaban disposition through examination of changes in absorption","volume":"38","author":"Kou","year":"2021","journal-title":"Pharm. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2015.10.022","article-title":"Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies","volume":"220","author":"Koziolek","year":"2015","journal-title":"J. Control. Release"},{"key":"B62","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/J.EJPS.2019.04.003","article-title":"The mechanisms of pharmacokinetic food-drug interactions - a perspective from the UNGAP group","volume":"134","author":"Koziolek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/PHARMACEUTICS13020283","article-title":"On absorption modeling and food effect prediction of rivaroxaban, a BCS II drug orally administered as an immediate-release tablet","volume":"13","author":"Kushwah","year":"2021","journal-title":"Pharmaceutics"},{"key":"B65","doi-asserted-by":"publisher","first-page":"10331","DOI":"10.3748\/WJG.V20.I30.10331","article-title":"Helicobacter pylori infection and drugs malabsorption","volume":"20","author":"Lahner","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B67","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/PHARMACEUTICS15030907","article-title":"Preparation of apixaban solid dispersion for the enhancement of apixaban solubility and permeability","volume":"15","author":"Lee","year":"2023","journal-title":"Pharmaceutics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac","year":"2010","journal-title":"Implement Sci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1080\/03639045.2020.1810263","article-title":"Pharmacokinetics and bioequivalence of a generic empagliflozin tablet versus a brand-named product and the food effects in healthy Chinese subjects","volume":"46","author":"Li","year":"","journal-title":"Drug Dev. Ind. Pharm."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e00593","DOI":"10.1002\/PRP2.593","article-title":"Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions","volume":"8","author":"Li","year":"","journal-title":"Pharmacol. Res. Perspect."},{"key":"B71","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/CPDD.908","article-title":"Pharmacokinetics and pharmacodynamics of ertugliflozin in healthy Japanese and Western subjects","volume":"10","author":"Li","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B72","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0009-9236(98)90130-8","article-title":"Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors","volume":"64","author":"Lilja","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/CP.1999.V66.100453001","article-title":"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin","volume":"66","author":"Lilja","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"B74","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/J.JACC.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and Statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/CPDD.1156","article-title":"Bioequivalence and pharmacokinetic study of 2 edoxaban tablets in healthy Chinese subjects","volume":"11","author":"Liu","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"873","DOI":"10.5414\/CP201948","article-title":"Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers","volume":"51","author":"Macha","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/EJCN.2013.78","article-title":"Delayed gastric emptying and reduced postprandial small bowel water content of equicaloric whole meal bread versus rice meals in healthy subjects: novel MRI insights","volume":"67","author":"Marciani","year":"2013","journal-title":"Eur. J. Clin. Nutr."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/EURHEARTJ\/EHAD192","article-title":"ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/EJHF.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (ESC). With the special contribution of the heart failure association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"B81","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/EJHF.3024","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2023","journal-title":"Eur. J. Heart Fail"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(17)31071-1","article-title":"Heart failure","volume":"390","author":"Metra","year":"2017","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1021\/MP400256H","article-title":"Impaired drug absorption due to high stomach pH: a review of strategies for mitigation of such effect to enable pharmaceutical product development","volume":"10","author":"Mitra","year":"2013","journal-title":"Mol. Pharm."},{"key":"B87","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/BF00176554","article-title":"Influence of the menstrual cycle and of menopause on the gastric emptying rate of solids in female volunteers","volume":"20","author":"Mon\u00e9s","year":"1993","journal-title":"Eur. J. Nucl. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/CPDD.123","article-title":"Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube","volume":"3","author":"Moore","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"256","DOI":"10.5414\/CP202233","article-title":"Effect of food on the pharmacokinetics of canagliflozin\/metformin (150\/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants","volume":"53","author":"Murphy","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/138920021609151201113537","article-title":"Interaction of drug or food with drug transporters in intestine and liver","volume":"16","author":"Nakanishi","year":"2015","journal-title":"Curr. Drug Metab."},{"key":"B91","doi-asserted-by":"publisher","first-page":"104023","DOI":"10.1016\/j.xphs.2025.104023","article-title":"Biowaiver monograph for immediate-release solid oral dosage forms: empagliflozin","volume":"114","author":"Negoya","year":"2025","journal-title":"J. Pharm. Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/S40262-024-01466-0\/TABLES\/4","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/oxfordjournals.bmb.a072252","article-title":"Effect of anaesthesia and surgery on pharmacokinetics and pharmacodvamics","volume":"44","author":"Nimmo","year":"1988","journal-title":"Br. Med. Bull."},{"key":"B94","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14740338.5.3.433","article-title":"Warfarin and its interactions with foods, herbs and other dietary supplements","volume":"5","author":"Nutescu","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"B95","first-page":"343","article-title":"Effect of food on the bioavailability of empagliflozin\/linagliptin combination tablet in healthy Japanese Male adults: - a randomized, single-dose, two-sequence crossover study","volume":"46","author":"Osonoi","year":"2018","journal-title":"Jpn. Pharmacol. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"B98","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/EMERMED-2015-204891","article-title":"Coagulation assessment with the new generation of oral anticoagulants","volume":"33","author":"Pollack","year":"2015","journal-title":"Emerg. Med. J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/CTS.12549","article-title":"Novel application of the two-period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin","volume":"11","author":"Raje","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/BIOMEDICINES12051030","article-title":"Small intestinal bacterial overgrowth (SIBO) and twelve groups of related diseases\u2014current state of knowledge","volume":"12","author":"Roszkowska","year":"2024","journal-title":"Biomedicines"},{"key":"B101","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/S11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"B102","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/S11894-009-0070-Y","article-title":"Gastric infection by Helicobacter pylori","volume":"11","author":"Sachs","year":"2009","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2174\/2772432817666220531115314","article-title":"A systematic review of randomized clinical trials on the efficacy and safety of pitavastatin","volume":"18","author":"Sadeq","year":"2023","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/CPDD.629","article-title":"Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin\/sitagliptin and ertugliflozin\/metformin","volume":"8","author":"Sahasrabudhe","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B105","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/J.1365-2036.2005.02683.X","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B106","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3109\/00498254.2015.1046153","article-title":"The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese Male subjects","volume":"46","author":"Shang","year":"2016","journal-title":"Xenobiotica"},{"key":"B107","first-page":"203","article-title":"Genetic polymorphisms, drug metabolism and drug concentrations","volume":"25","author":"Shenfield","year":"2004","journal-title":"Clin. Biochem. Rev."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1007\/S10620-005-3048-0","article-title":"Regional postprandial differences in pH within the stomach and gastroesophageal junction","volume":"50","author":"Simonian","year":"2005","journal-title":"Dig. Dis. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/J.JCHF.2021.11.006","article-title":"Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial","volume":"10","author":"Solomon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/J.CLINTHERA.2015.05.497","article-title":"Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects","volume":"37","author":"Song","year":"2015","journal-title":"Clin. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/J.CLINTHERA.2016.05.004","article-title":"Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults","volume":"38","author":"Song","year":"2016","journal-title":"Clin. Ther."},{"key":"B112","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1002\/jps.24103","article-title":"On the colonic bacterial metabolism of Azo-bonded prodrugs of 5-aminosalicylic acid","volume":"103","author":"Sousa","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"B113","doi-asserted-by":"publisher","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"B114","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"105280","DOI":"10.1016\/j.ejps.2020.105280","article-title":"Impact of gastrointestinal physiology on drug absorption in special populations\u2013\u2013an UNGAP review","volume":"147","author":"Stillhart","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/J.PARKRELDIS.2017.02.029","article-title":"A practical review of gastrointestinal manifestations in Parkinson\u2019s disease","volume":"39","author":"Su","year":"2017","journal-title":"Park. Relat. Disord."},{"key":"B117","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/CPDD.131","article-title":"Effect of food on the oral bioavailability of amlodipine\/valsartan and amlodipine\/valsartan\/hydrochlorothiazide fixed dose combination tablets in healthy subjects","volume":"3","author":"Sunkara","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/BCP.14404","article-title":"Warfarin and food, herbal or dietary supplement interactions: a systematic review","volume":"87","author":"Tan","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/J.CLINTHERA.2019.05.015","article-title":"Bioequivalence and food effect of dapagliflozin\/saxagliptin\/metformin extended-release fixed-combination drug products compared with coadministration of the individual components in healthy subjects","volume":"41","author":"Tang","year":"2019","journal-title":"Clin. Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2146\/AJHP120689","article-title":"Drug absorption in celiac disease","volume":"70","author":"Tran","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B121","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1111\/CTS.13677","article-title":"Vericiguat, a novel sGC stimulator: mechanism of action, clinical, and translational science","volume":"16","author":"Trujillo","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/J.1742-1241.2012.03008.X","article-title":"Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review","volume":"66","author":"Tsai","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/PRP2.201","article-title":"Bioequivalence of saxagliptin\/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects","volume":"3","author":"Vakkalagadda","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"B125","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/EURHEARTJ\/EHAE176","article-title":"ESC guidelines for the management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur. Heart J."},{"key":"B126","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/S40262-023-01223-9","article-title":"Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: a randomised trial in healthy subjects","volume":"62","author":"van Hout","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B127","doi-asserted-by":"publisher","first-page":"517","DOI":"10.11124\/JBIES-24-00308","article-title":"Update to the PRISMA guidelines for network meta-analyses and scoping reviews and development of guidelines for rapid reviews: a scoping review protocol","volume":"23","author":"Veroniki","year":"2025","journal-title":"JBI Evid. Synth."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/EURHEARTJ\/EHAE177","article-title":"ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"B129","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/J.1742-1241.2009.02286.X","article-title":"Drug and dietary interactions of the new and emerging oral anticoagulants","volume":"64","author":"Walenga","year":"2010","journal-title":"Int. J. Clin. Pract."},{"key":"B130","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s40261-015-0343-1","article-title":"Prevalence of desloratadine slow-metabolizer phenotype and food-dependent pharmacokinetics of desloratadine in healthy Chinese volunteers","volume":"35","author":"Wang","year":"2015","journal-title":"Clin. Drug Investig."},{"key":"B131","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/CTS.13426","article-title":"Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study","volume":"16","author":"Wang","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/DDDT.S497515","article-title":"Impact of food physical properties on oral drug absorption","volume":"19","author":"Wang","year":"2025","journal-title":"A Compr. Rev."},{"key":"B133","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1124\/jpet.109.154542","article-title":"Lymphatic transport of methylnortestosterone undecanoate (MU) and the bioavailability of methylnortestosterone are highly sensitive to the mass of coadministered lipid after oral administration of MU","volume":"331","author":"White","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/JPEN.1157","article-title":"Insights into the different effects of food on intestinal secretion using magnetic resonance imaging","volume":"42","author":"Wilkinson-Smith","year":"2018","journal-title":"J. Parenter. Enter. Nutr."},{"key":"B135","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pharmthera.2012.08.001","article-title":"Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport","volume":"136","author":"Won","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"B136","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/S11095-004-9004-4","article-title":"Predicting drug disposition via application of BCS: transport\/absorption\/elimination interplay and development of a biopharmaceutics drug disposition classification system","volume":"22","author":"Wu","year":"2005","journal-title":"Pharm. Res."},{"key":"B137","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: a systematic review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des. Devel Ther."},{"key":"B138","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/PHARMACY9020076","article-title":"A questionnaire-based survey to assess the level of knowledge and awareness about drug\u2013food interactions among general public in Western Saudi Arabia","volume":"9","author":"Zaidi","year":"2021","journal-title":"Pharm. J. Pharm. Educ. Pract."},{"key":"B139","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/S00394-020-02421-Y","article-title":"The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies","volume":"60","author":"Zarezadeh","year":"2020","journal-title":"Eur. J. Nutr."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1102521","DOI":"10.3389\/fcvm.2023.1102521","article-title":"The history and mystery of sacubitril\/valsartan: from clinical trial to the real world","volume":"10","author":"Zhang","year":"2023","journal-title":"Front. Cardiovasc Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1786007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:10:43Z","timestamp":1777277443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1786007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":140,"alternative-id":["10.3389\/fphar.2026.1786007"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1786007","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1786007"}}